Financial reports
10-Q
2021 Q2
Quarterly report
5 Aug 21
10-Q
2021 Q1
Quarterly report
13 May 21
10-K
2020 FY
Annual report
9 Mar 21
10-Q
2020 Q3
Quarterly report
9 Nov 20
10-Q
2020 Q2
Quarterly report
10 Aug 20
10-Q
2020 Q1
Quarterly report
7 May 20
10-K
2019 FY
Annual report
12 Mar 20
10-Q
2019 Q3
Quarterly report
7 Nov 19
10-Q
2019 Q2
Quarterly report
6 Aug 19
10-Q
2019 Q1
Quarterly report
9 May 19
Current reports
8-K
Completion of Acquisition or Disposition of Assets
5 Oct 21
8-K
Entry into a Material Definitive Agreement
5 Oct 21
8-K
Xeris Pharmaceuticals Stockholders Approve Acquisition of Strongbridge Biopharma
14 Sep 21
8-K
Xeris Pharmaceuticals Reports Second Quarter 2021 Financial Results and Recent Highlights
5 Aug 21
8-K
Xeris Pharmaceuticals, Inc. Provides Announcement under the Irish Takeover Rules for Relevant Securities in Issue
30 Jul 21
8-K
Xeris Pharmaceuticals Announces Executive Changes As Part of Its Strategy to Position the Company for Long-term Commercial Success
29 Jul 21
8-K
Xeris Pharmaceuticals Enters into an Exclusive License and Supply Agreement with Tetris Pharma Limited to Commercialize Ogluo® In Europe
19 Jul 21
8-K
Submission of Matters to a Vote of Security Holders
8 Jun 21
8-K
This Announcement Is Being Made Pursuant to Rule 2.5 of the Irish Takeover Rules
24 May 21
8-K
Xeris Pharmaceuticals Reports First Quarter 2021 Financial Results and Recent Highlights
13 May 21
Registration and prospectus
15-12B
Securities registration termination
15 Oct 21
25-NSE
Exchange delisting
5 Oct 21
POS AM
Prospectus update (post-effective amendment)
5 Oct 21
S-8 POS
Registration of securities for employees (post-effective amendment)
5 Oct 21
S-8 POS
Registration of securities for employees (post-effective amendment)
5 Oct 21
S-8 POS
Registration of securities for employees (post-effective amendment)
5 Oct 21
S-8 POS
Registration of securities for employees (post-effective amendment)
5 Oct 21
425
Business combination disclosure
13 Sep 21
425
Business combination disclosure
30 Aug 21
425
Business combination disclosure
30 Aug 21
Proxies
DEFM14A
Proxy related to merger
29 Jul 21
DEFA14A
Additional proxy soliciting materials
29 Apr 21
DEF 14A
Definitive proxy
29 Apr 21
DEFA14A
Additional proxy soliciting materials
25 Sep 20
DEFA14A
Additional proxy soliciting materials
16 Sep 20
DEF 14A
Definitive proxy
2 Sep 20
PRE 14A
Preliminary proxy
18 Aug 20
DEFA14A
Additional proxy soliciting materials
24 Apr 20
DEF 14A
Definitive proxy
24 Apr 20
DEFA14A
Additional proxy soliciting materials
26 Mar 19
Other
EFFECT
Notice of effectiveness
7 Oct 21
EFFECT
Notice of effectiveness
22 Aug 19
CORRESP
Correspondence with SEC
19 Aug 19
UPLOAD
Letter from SEC
8 Aug 19
EFFECT
Notice of effectiveness
13 Feb 19
CORRESP
Correspondence with SEC
11 Feb 19
CORRESP
Correspondence with SEC
11 Feb 19
UPLOAD
Letter from SEC
8 Feb 19
EFFECT
Notice of effectiveness
21 Jun 18
CT ORDER
Confidential treatment order
21 Jun 18
Ownership
SC 13G/A
Sessa Capital (Master), L.P.
14 Feb 22
4
BARBARA-JEAN ANNE BORMANN-KENNEDY
5 Oct 21
4
JEFFREY W SHERMAN
5 Oct 21
4
John P. Schmid
5 Oct 21
4
DAWN HALKUFF
5 Oct 21
4
Paul R Edick
5 Oct 21
4
Steven Pieper
5 Oct 21
4
STEVEN PRESTRELSKI
5 Oct 21
4
Beth Hecht
5 Oct 21
4
KENNETH ERLAND JOHNSON
5 Oct 21